Literature DB >> 3475033

Failure of newer beta-lactam antibiotics for murine Yersinia enterocolitica infection.

M R Scavizzi, J M Alonso, A M Philippon, A M Jupeau-Vessieres, A Guiyoule.   

Abstract

Cefotaxime, imipenem, gentamicin, and doxycycline were active in vitro against the virulent serotype O8 Yersinia enterocolitica WA strain. Amoxycillin was inactive. The in vivo activity of these drugs was evaluated in a standardized and reproducible mouse model of systemic infection. Each single antibiotic was injected intravenously 30 h after intravenous inoculation of Y. enterocolitica WA. In vivo efficacy was measured by counting the viable bacteria recovered from the whole spleens of mice sacrificed at selected times. Doxycycline and gentamicin were active in stopping bacterial proliferation. Cefotaxime and imipenem, even at high doses (250 and 100 mg/kg of body weight, respectively), were totally ineffective, as was amoxycillin. Bacterial inocula (10(7)), recovered from either the in vitro growth or the infected spleens, were plated on cefotaxime or imipenem concentration gradients in agar; no emergence of beta-lactam-resistant organisms was detected. Based on these experiments it is not possible to explain, from any given property of the antibiotic, the bacteria, or the host, the discrepancy between the in vivo and in vitro activities of cefotaxime and imipenem. On the basis of these results, the use of newer beta-lactam antibiotics should be delayed in the therapy of human Y. enterocolitica infections until further investigations are carried out.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3475033      PMCID: PMC174770          DOI: 10.1128/AAC.31.4.523

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Generalized Yersinia enterocolitica infection.

Authors:  A R Rabson; A F Hallett; H J Koornhof
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

2.  Beta-lactamases from Yersinia enterocolitica.

Authors:  G Cornelis; E P Abraham
Journal:  J Gen Microbiol       Date:  1975-04

3.  Plasmid-mediated and temperature-regulated surface properties of Yersinia enterocolitica.

Authors:  R J Martinez
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

4.  [Experimental infection in mice with Yersinia enterocolitica (strain biotype 4, serogroup O:3, phage type VIII): growth of the inoculum in athymic or cyclophosphamide treated mice (author's transl)].

Authors:  J M Alonso; D Mazigh; H Bercovier; H H Mollaret
Journal:  Ann Microbiol (Paris)       Date:  1978-07

5.  Correlation of autoagglutination and virulence of yersiniae.

Authors:  W J Laird; D C Cavanaugh
Journal:  J Clin Microbiol       Date:  1980-04       Impact factor: 5.948

6.  Yersinia enterocolitica: comparative in vitro activities of seven new beta-lactam antibiotics.

Authors:  R K Scribner; M I Marks; A Weber; C H Pai
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

7.  The susceptibility of Yersinia to eleven antimicrobials.

Authors:  F Soriano; J Vega
Journal:  J Antimicrob Chemother       Date:  1982-12       Impact factor: 5.790

8.  Specificity of beta-lactamase induction in Pseudomonas aeruginosa.

Authors:  A Dalhoff; W Cullmann
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

9.  Plasmids of human strains of Yersinia enterocolitica: molecular relatedness and possible importance for pathogenesis.

Authors:  J Heesemann; C Keller; R Morawa; N Schmidt; H J Siemens; R Laufs
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

10.  In vitro susceptibilities of 126 clinical isolates of Yersinia enterocolitica to 21 beta-lactam antibiotics.

Authors:  M J Hornstein; A M Jupeau; M R Scavizzi; A M Philippon; P A Grimont
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  11 in total

1.  Endocarditis due to Yersinia enterocolitica.

Authors:  E Bonnet; M Archambaud; A Sommabere; C Suc; Z Elias; M Gallinier; P Massabuau; J P Bounhoure; P Massip
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

Review 2.  Optimum treatment of intracellular infection.

Authors:  M Maurin; D Raoult
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

3.  In vitro antimicrobial susceptibilities of strains of Yersinia pestis.

Authors:  M D Smith; D X Vinh; T T Nguyen; J Wain; D Thung; N J White
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 4.  Yersinia enterocolitica causing suppurative arthritis of the shoulder.

Authors:  F Tiddia; G B Cherchi; L Pacifico; C Chiesa
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

Review 5.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

6.  Bacterial colitis.

Authors:  Harry T Papaconstantinou; J Scott Thomas
Journal:  Clin Colon Rectal Surg       Date:  2007-02

Review 7.  Yersinia enterocolitica endocarditis: case report and literature review.

Authors:  H Giamarellou; A Antoniadou; K Kanavos; C Papaioannou; S Kanatakis; K Papadaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

8.  Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection.

Authors:  S P Bonacorsi; M R Scavizzi; A Guiyoule; J H Amouroux; E Carniel
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection.

Authors:  B C Lemaitre; D A Mazigh; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

10.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Authors:  J L Fournier; F Ramisse; A C Jacolot; M Szatanik; O J Petitjean; J M Alonso; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.